Therapeutic manipulation of peroxynitrite attenuates the development of opiate-induced antinociceptive tolerance in mice.
Severe pain syndromes reduce quality of life in patients with inflammatory and neoplastic diseases, often because chronic opiate therapy results in reduced analgesic effectiveness, or tolerance, leading to escalating doses and distressing side effects. The mechanisms leading to tolerance are poorly understood. Our studies revealed that development of antinociceptive tolerance to repeated doses of morphine in mice was consistently associated with the appearance of several tyrosine-nitrated proteins in the dorsal horn of the spinal cord, including the mitochondrial isoform of superoxide (O2-) dismutase, the glutamate transporter GLT-1, and the enzyme glutamine synthase. Furthermore, antinociceptive tolerance was associated with increased formation of several proinflammatory cytokines, oxidative DNA damage, and activation of the nuclear factor poly(ADP-ribose) polymerase. Inhibition of NO synthesis or removal of O2- blocked these biochemical changes and inhibited the development of tolerance, pointing to peroxynitrite (ONOO-), the product of the interaction between O2- and NO, as a signaling mediator in this setting. Indeed, coadministration of morphine with the ONOO- decomposition catalyst, Fe(III) 5,10,15,20-tetrakis(N-methylpyridinium-4-yl)porphyrin, blocked protein nitration, attenuated the observed biochemical changes, and prevented the development of tolerance in a dose-dependent manner. Collectively, these data suggest a causal role for ONOO- in pathways culminating in antinociceptive tolerance to opiates. Peroxynitrite (ONOO-) decomposition catalysts may have therapeutic potential as adjuncts to opiates in relieving suffering from chronic pain.
Muscoli
Carolina
C
Faculty of Pharmacy, University of Catanzaro Magna Graecia, Roccelletta di Borgia, Catanzaro, Italy.
Cuzzocrea
Salvatore
S
Ndengele
Michael M
MM
Mollace
Vincenzo
V
Porreca
Frank
F
Fabrizi
Francesca
F
Esposito
Emanuela
E
Masini
Emanuela
E
Matuschak
George M
GM
Salvemini
Daniela
D
D000701:Analgesics, Opioid / Q000378:metabolism* / Q000627:therapeutic use; D000818:Animals; D016207:Cytokines / Q000378:metabolism; D004249:DNA Damage; D004361:Drug Tolerance / Q000502:physiology*; D004791:Enzyme Inhibitors / Q000378:metabolism; D016166:Free Radical Scavengers / Q000378:metabolism; D006801:Humans; D008297:Male; D008665:Metalloporphyrins / Q000378:metabolism; D051379:Mice; D019331:NG-Nitroarginine Methyl Ester / Q000378:metabolism; D010146:Pain / Q000188:drug therapy; D017288:Pain Threshold / Q000502:physiology*; D030421:Peroxynitrous Acid / Q000378:metabolism*; D011065:Poly(ADP-ribose) Polymerases / Q000378:metabolism; D011166:Porphyrins / Q000737:chemistry / Q000378:metabolism; D051381:Rats; D013116:Spinal Cord / Q000166:cytology / Q000378:metabolism; D013482:Superoxide Dismutase / Q000378:metabolism; D014443:Tyrosine / Q000031:analogs & derivatives / Q000378:metabolism
D000701:Analgesics, Opioid; D016207:Cytokines; D004791:Enzyme Inhibitors; D016166:Free Radical Scavengers; D008665:Metalloporphyrins; D011166:Porphyrins; C097284:manganese(III)-tetrakis(4-benzoic acid)porphyrin; D030421:Peroxynitrous Acid; C002744:3-nitrotyrosine; D014443:Tyrosine; D013482:Superoxide Dismutase; D011065:Poly(ADP-ribose) Polymerases; D019331:NG-Nitroarginine Methyl Ester